X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1051) 1051
Publication (136) 136
Patent (13) 13
Book Chapter (8) 8
Book Review (5) 5
Book / eBook (4) 4
Conference Proceeding (4) 4
Web Resource (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (545) 545
oncology (420) 420
male (344) 344
female (341) 341
middle aged (303) 303
index medicus (290) 290
cancer (287) 287
aged (268) 268
adult (228) 228
chemotherapy (214) 214
adenocarcinoma (194) 194
surgery (185) 185
esophageal cancer (157) 157
prognosis (136) 136
antineoplastic combined chemotherapy protocols - therapeutic use (131) 131
esophageal neoplasms - pathology (130) 130
adenocarcinoma - pathology (119) 119
carcinoma (117) 117
care and treatment (113) 113
treatment outcome (113) 113
aged, 80 and over (111) 111
combined modality therapy (111) 111
stomach cancer (111) 111
stomach neoplasms - drug therapy (110) 110
retrospective studies (107) 107
stomach neoplasms - pathology (105) 105
neoplasm staging (104) 104
survival (102) 102
esophageal neoplasms - therapy (100) 100
gastric cancer (99) 99
adenocarcinoma - therapy (91) 91
chemoradiotherapy (89) 89
survival rate (89) 89
adenocarcinoma - drug therapy (87) 87
esophageal neoplasms - drug therapy (87) 87
chemoradiation (80) 80
esophageal neoplasms - mortality (80) 80
radiotherapy (80) 80
research (77) 77
fluorouracil - administration & dosage (75) 75
adenocarcinoma - mortality (74) 74
article (73) 73
survival analysis (73) 73
therapy (69) 69
medicine & public health (66) 66
squamous-cell carcinoma (65) 65
cisplatin - administration & dosage (64) 64
neoadjuvant therapy (63) 63
metastasis (57) 57
antineoplastic agents - therapeutic use (55) 55
patient outcomes (55) 55
disease-free survival (54) 54
esophageal neoplasms - surgery (54) 54
stomach neoplasms - therapy (54) 54
chemotherapy, adjuvant (52) 52
fluorouracil (52) 52
adenocarcinoma - surgery (51) 51
cisplatin (51) 51
esophageal neoplasms - radiotherapy (50) 50
stomach neoplasms - mortality (50) 50
esophagogastric junction (49) 49
randomized-trial (49) 49
esophagus (48) 48
gastrectomy (48) 48
health aspects (48) 48
abridged index medicus (47) 47
stomach neoplasms - surgery (46) 46
analysis (44) 44
phase-iii trial (44) 44
risk factors (44) 44
esophagectomy (42) 42
gastroenterology & hepatology (41) 41
antineoplastic combined chemotherapy protocols - adverse effects (40) 40
follow-up studies (40) 40
patients (39) 39
preoperative chemoradiation (39) 39
5-fluorouracil (37) 37
animals (37) 37
cell biology (37) 37
lymphatic metastasis (37) 37
trial (37) 37
tumors (37) 37
drug administration schedule (36) 36
proportional hazards models (36) 36
surgical oncology (36) 36
adenocarcinoma - genetics (35) 35
breast-cancer (35) 35
esophageal neoplasms - genetics (35) 35
stomach neoplasms - genetics (35) 35
expression (34) 34
carcinoma, squamous cell - therapy (33) 33
phase-ii trial (33) 33
radiology, nuclear medicine & medical imaging (33) 33
multivariate analysis (32) 32
esophagogastric junction - pathology (31) 31
mortality (31) 31
radiation (31) 31
adenocarcinoma - radiotherapy (30) 30
carcinoma, squamous cell - drug therapy (30) 30
carcinoma, squamous cell - pathology (30) 30
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Summary Background Although trastuzumab plus chemotherapy is the standard of care for first-line treatment of HER2-positive advanced gastric cancer, there is... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | SUPPORTIVE CARE | WEEKLY PACLITAXEL | ONCOLOGY | 2ND-LINE CHEMOTHERAPY | IRINOTECAN | LEVEL | PLUS PACLITAXEL | HER2 | CANCER | DOCETAXEL | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis
Journal Article
Journal Article